CME in Minutes: Education in Primary Care: Recent Episodes
Answers in CME
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.
Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
Please visit answersincme.com/JTB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric epilepsy discusses strategies for optimizing the care of children and adults with Lennox-Gastaut syndrome (LGS). Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to accurately recognize LGS in children and adults; Evaluate the latest pharmacologic treatment strategies available for patients with LGS; and Outline approaches to optimize the long-term care of patients with LGS.
Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.
Please visit answersincme.com/FXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infectious disease discusses management of refractory Mycobacterium avium complex (MAC) pulmonary disease. Upon completion of this activity, participants should be better able to: Identify patients with refractory Mycobacterium avium complex (MAC) pulmonary disease in a timely manner; Review guideline-recommended therapeutic approaches to enhance the treatment plan for patients with refractory MAC pulmonary disease; and Outline clinical strategies to optimize long-term care for patients with refractory MAC pulmonary disease.
Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,
Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.
Please visit answersincme.com/BCK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses the latest data in anti-CD38 quadruplet regimens in newly diagnosed multiple myeloma. Upon completion of this activity, participants should be better able to: Identify the role of anti-CD38 monoclonal antibody (mAB)–based quadruplet regimens in the treatment landscape for newly diagnosed multiple myeloma (NDMM); Review the latest clinical data of anti-CD38 mAB-based quadruplet regimens for transplant-ineligible patients with NDMM; and Analyze evidence-based strategies for optimizing outcomes with anti-CD38 mAB-based quadruplet regimens in patients with transplant-ineligible NDMM.
Please visit answersincme.com/WKB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses early-stage Alzheimer’s Disease (AD). Upon completion of this activity, participants should be better able to: Describe the multidisciplinary process of screening patients for early-stage AD; Describe the role primary care providers play in the multidisciplinary process of diagnosing patients with early-stage AD; and Outline strategies for counseling patients and caregivers about early intervention for early-stage AD.
Please visit answersincme.com/TDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metabolic diseases discusses metachromatic leukodystrophy (MLD). Upon completion of this activity, participants should be better able to: Explain the clinical burden and unmet needs in MLD; Describe the signs and symptoms of MLD to facilitate early diagnosis and intervention; and Outline potential strategies to optimize outcomes for patients with MLD.
Please visit answersincme.com/BPB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses the latest guidelines and evidence for later-line treatment of metastatic colorectal cancer (mCRC), as well as strategies for treatment selection and survivorship care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the later-line treatment of mCRC; Discuss the clinical impact of approved later-line treatments in patients with mCRC; and Outline personalized strategies to optimize outcomes for patients with mCRC who require later-line treatment.
Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.
Please visit answersincme.com/XCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in urology discuss the latest data for treatments of overactive bladder. Upon completion of this activity, participants should be better able to: Review the current treatment landscape of OAB; Discuss the clinical significance of the latest efficacy and safety data for beta-3 adrenergic agonists for the treatment of OAB; and Outline evidence-based, patient-centered strategies to optimally use beta-3 adrenergic agonists for the treatment of patients with OAB.
Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.
Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.
Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.
Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.
Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.
Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.
Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.
Please visit answersincme.com/YZW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses biologic therapy for prurigo nodularis, and a patient presents her perspective. Upon completion of this activity, participants should be better able to: Identify the therapeutic needs of patients with PN; Review the evidence for current and emerging biologic treatments for PN; and Outline how to integrate biologic therapies into the care of patients with PN.
Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.
Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist’s partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.
Please visit answersincme.com/KWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in bipolar disorder and a patient advocate discuss patient-centered care for people with bipolar I. Upon completion of this activity, participants should be better able to: Identify patient-centered strategies to optimize the timely diagnosis of bipolar I disorder (BD-I); Review goal-oriented therapeutic approaches that address the personalized needs of patients with BD-I; and Outline strategies to ensure the delivery of patient-centric care that incorporates patients’ wishes, values, priorities, and goals.
Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.
Please visit answersincme.com/93496951-replay2860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.
Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline treatment of PTCL; Describe the clinical evidence informing the use of CD30-directed therapy in frontline treatment of PTCL; and Outline considerations to optimize outcomes with CD30-directed therapy for frontline treatment of patients with PTCL.
Please visit answersincme.com/WSK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Evan S. Dellon, MD, MPH, an expert in esophageal disease, discusses best practices to facilitate timely diagnosis of eosinophilic esophagitis (EoE) through symptom recognition and referral at the emergency department. Upon completion of this activity, participants should be better able to: Recognize the consequences of untreated eosinophilic esophagitis (EoE), including the burden of food impaction; Identify best practices to facilitate the timely diagnosis and management of EoE through symptom recognition and referral; and Review the available therapeutic modalities for EoE that support the need for timely referral. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.
Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.
Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.
Please visit answersincme.com/VAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women's health and menopause discusses novel, nonhormonal strategies to treat vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel nonhormonal therapies in the treatment of VMS associated with menopause; Review the clinical profiles of approved and emerging novel nonhormonal treatments of VMS associated with menopause; Outline patient-centered, evidence-based strategies to optimize the treatment of common menopausal symptoms
Please visit answersincme.com/UYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses novel treatment options being investigated for patients with Alzheimer’s disease psychosis (ADP). Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in managing patients with Alzheimer’s disease psychosis (ADP); Review the rationale for using therapies with novel mechanisms for the treatment of patients with ADP; Describe the implications of the latest data on novel therapies for managing patients with ADP.
Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients
Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care
Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/YCT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with asthma who may benefit from treatment intensification with biologic therapy; Outline the clinical impact of add-on biologics approved for the treatment of pediatric patients with moderate to severe asthma; and Identify patient-centered strategies to optimize outcomes for pediatric patients with inadequately controlled moderate to severe asthma. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.
Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.
Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.
Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.
Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.
Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC); Identify patient- and disease-based factors which guide the use of TKI therapy for the treatment of advanced HCC; and Outline strategies to develop personalized treatment plans to maximize clinical outcomes using TKI therapies in the treatment of advanced HCC.
Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.
Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.
Please visit answersincme.com/UWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses chemoimmunotherapy treatment of advanced squamous cell non-small cell lung cancer without molecular alterations. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of approved chemoimmunotherapy combinations for treatment of patients with advanced squamous cell non-small cell lung cancer (NSCLC) without molecular alterations; Review clinical factors for individualizing first-line treatment of patients with advanced squamous cell NSCLC; and Identify real-world factors that impact treatment selection for patients with advanced squamous cell NSCLC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/CKZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses patient-centered approaches to the diagnosis and treatment of biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the importance of achieving an accurate diagnosis of biliary tract cancer (BTC); Outline strategies for reaching a diagnosis of BTC, including cholangiocarcinoma; and Describe patient-centered approaches to enhance outcomes for patients undergoing a diagnostic work-up for BTC.
Please visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating novel CELMoDs in the maintenance and earlier-relapse settings in the future treatment landscape of MM.
Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.
Please visit answersincme.com/KQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in narcolepsy discusses the evaluation and treatment of patients with narcolepsy and cardiovascular disease. Upon completion of this activity, participants should be better able to: Explain the rationale for evaluating patients with narcolepsy for cardiovascular (CV) risk; Review the clinical profiles of guideline-recommended treatment options for narcolepsy, including impact on CV risk; and Outline real-world clinical strategies to optimize long-term management of patients with narcolepsy, including those at risk of CV disease.
Please visit answersincme.com/VMK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of novel therapies for patients with transfusion-dependent beta thalassemia. Upon completion of this activity, participants should be better able to: Describe the limitations of ongoing transfusions for patients with transfusion-dependent beta thalassemia (TDT); Review the evidence on novel therapies for TDT; and Outline shared decision-making strategies for the potential use of novel therapies for patients with TDT.
Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.
Please visit answersincme.com/XFG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in vascular neurology discusses the data and the implications for inhibiting coagulation factor XIa (FXIa) as a therapeutic option in stroke prevention. Upon completion of this activity, participants should be better able to: Identify the rationale for inhibiting FXIa as a therapeutic option in stroke prevention; Describe the latest clinical data for oral FXIa inhibitors in stroke prevention; and Review the implications of the latest FXIa inhibitor data for the future of stroke prevention.
Please visit answersincme.com/TSH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of metastatic colorectal cancer (mCRC) discuss sequencing strategies to enhance patient quality of life during later-line treatment. Upon completion of this activity, participants should be better able to: Describe the latest data for later-line treatment sequencing for patients with mCRC; Outline evidence-based strategies to optimally sequence later-line treatment options for mCRC; and Explain tactics for addressing quality of life and survivorship with patients in later lines of treatment for mCRC.
Please visit answersincme.com/NVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics and immunology discusses the continued burden of respiratory syncytial virus (RSV) in infants and strategies to increase vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) prevention in infants; Review the clinical profiles of national guideline-recommended RSV prophylactic agents in infants; and Outline patient-centered strategies to optimize the uptake of RSV prophylactic options in infants.
Please visit answersincme.com/CGH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses evidence and guidance on using multimodal approaches for managing patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Upon completion of this activity, participants should be better able to: Identify the continued needs with the currently available therapies for inoperable CTEPH; Review the clinical evidence for multimodal approaches in inoperable CTEPH in the context of currently available therapies; and Outline clinical factors that may facilitate optimal therapeutic selection for patients with inoperable CTEPH.
Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.
Please visit answersincme.com/FPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the diagnosis and pharmacological management of Lennox-Gastaut syndrome (LGS), and is joined by a patient advocate to discuss the impact of LGS on patients and their families. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of LGS on the lives of patients with the disease and their families; Outline strategies to accurately diagnose LGS in children and adults; and Describe the pharmacological treatment options available for patients with LGS.
Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.
Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.
Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.
Please visit answersincme.com/MVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology and a patient advocate discuss strategies to optimize care for patients with metastatic breast cancer using antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Identify the rationale for targeted antibody-drug conjugates (ADCs) in the treatment of patients with metastatic breast cancer (mBC); Review strategies to enhance safety of the available ADCs for the treatment of mBC; and Outline patient-focused strategies to optimize the use of ADCs in appropriate patients with mBC.
Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of neoadjuvant followed by adjuvant immunotherapy-based regimens in patients with resectable NSCLC; Describe current evidence on the use of neoadjuvant plus adjuvant immunotherapy in patients with resectable NSCLC; and Outline practical strategies to integrate neoadjuvant plus adjuvant immunotherapy-based regimens into the treatment plan for appropriate patients with resectable NSCLC.
Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.
Please visit answersincme.com/HRM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cancerous lymphoma discusses EZH2 and EZH1 inhibitors for the management of relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas. Upon completion of this activity, participants should be better able to: Describe the rationale for exploring EZH 2 and EZH1 inhibitors for the management of relapsed or refractory (R/R) B-cell and T-cell non-Hodgkin lymphomas (NHLs); Explain the mechanism of action (MOA) of EZH2 and EZH1 inhibition; and Review the clinical profiles of approved and emerging EZH2 and EZH1 inhibitors for R/R B-cell and T-cell NHLs.
Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.
Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the clinical profiles of novel CD20 x CD3 bispecific antibodies (BsAbs) for relapsing/refractory follicular lymphoma (R/R FL); Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL; and Outline evidence-based multidisciplinary strategies for optimal integration of BsAbs in the treatment plans of patients with R/R FL.
Please visit answersincme.com/GXD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses the evolving role of antibody-drug conjugates (ADCs) in HER2-expressing solid tumors. Upon completion of this activity, participants should be better able to: Recognize the role of human epidermal growth factor receptor 2 (HER2) in the pathogenesis of various solid tumors; Describe strategies to optimize HER2 biomarker testing in patients with various solid tumors; Review the evidence for HER2-directed antibody-drug conjugates (ADCs) that have demonstrated benefits in multiple types of HER2-expressing solid tumors; and Outline practical approaches to enhance outcomes for patients receiving HER2-directed ADCs for various solid tumors.
Please visit answersincme.com/DWQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in genetics discusses effective communication and treatment strategies for patients with phenylketonuria (PKU), including a patient’s perspective. Upon completion of this activity, participants should be better able to: Recognize the challenges adult patients with PKU face that impact quality of life; Discuss the impact of PKU on executive functioning in adult patients with PKU; and Practice effective patient-centered strategies to optimize care for adults with PKU.
Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.
Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.
Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.
Please visit answersincme.com/EFR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver disease discusses management of unresectable hepatocellular carcinoma through multiple lines of therapy. Upon completion of this activity, participants should be better able to: Identify clinical signs of progression on treatment for unresectable hepatocellular carcinoma (HCC) to enhance timely use of a sequential therapy; Describe the clinical impact of tyrosine kinase inhibitors for the real-world treatment of unresectable HCC; and Outline real-world clinical strategies to maximize the long-term treatment plan for patients with unresectable HCC through multiple lines of therapy.
Please visit answersincme.com/NFP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing postpartum depression discusses strategies to optimize the use of novel GABAergic neuroactive steroids for the management of patients with postpartum depression (PPD). Upon completion of this activity, participants should be better able to: Recognize the rationale for incorporating the GABAergic neuroactive steroids in the treatment of postpartum depression (PPD); Review the clinical evidence for the novel GABAergic neuroactive steroids in patients with PPD; and Outline patient-centered strategies for personalizing treatment with the novel GABAergic neuroactive steroids.
Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
Please visit answersincme.com/QHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses frontline chemoimmunotherapeutic regimens for unresectable advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Review guideline-recommended preferred frontline treatment regimens for unresectable advanced gastric or GEJ adenocarcinoma; Discuss clinical profiles of approved and late-stage emerging frontline immunotherapy-based chemotherapy combination regimens for unresectable advanced gastric or GEJ adenocarcinoma; and Outline practical considerations for optimizing treatment with frontline immunotherapy-based chemotherapy combination regimens in patients with unresectable advanced gastric or GEJ adenocarcinoma.
Please visit answersincme.com/FZX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the diagnosis and treatment of diabetic macular edema (DME), including the role of shared decision-making, with a patient’s perspective. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy among patients with DME.
Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the relevance of real-world evidence on the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Recognize ways that good quality real-world evidence (RWE) can complement findings from clinical trials in patients with HR+/HER2- metastatic breast cancer (mBC); Outline the clinical relevance of incorporating RWE on the frontline use of CDK4/6 inhibitors into shared decision-making with patients who have HR+/HER2- mBC; and Describe patient-centered strategies to integrate RWE into clinical decision-making discussions with patients who have HR+/HER2- mBC.
Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.
Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Please visit answersincme.com/MWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in coagulation disorders discusses the clinical impact of gene therapy in hemophilia A. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of gene therapy in the treatment of hemophilia A; Identify patients with hemophilia A who may be candidates for gene therapy; and Outline patient-centered monitoring strategies to optimize outcomes in patients with hemophilia A undergoing gene therapy.
Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.
Please visit answersincme.com/HEQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses how to optimize the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) using a case-based approach with perspectives from a patient. Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-VEGF therapies used in the treatment of nAMD; Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD; and Explain the importance of shared decision-making in the management of nAMD.
Please visit answersincme.com/UJD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in transgender medicine discusses improving approaches to guideline-concordant cervical cancer screening by healthcare professionals in patients who are transgender men or nonbinary. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of low uptake of cervical cancer screening among transgender men (TM) and people who identify as nonbinary (NB); Review key concerns experienced by TM and NB people that result in lower rates of cervical cancer screening; and Identify tailored strategies to enhance acceptance of cervical cancer screening in TM and people who identify as NB.
Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.
Please visit answersincme.com/TJX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses low-density lipoprotein (LDL) receptor–independent therapies for homozygous familial hypercholesterolemia (HoFH) via two patient case studies. Upon completion of this activity, participants should be better able to: Identify patients with HoFH through differential diagnosis; Review the clinical profiles of novel strategies to reduce LDL cholesterol in patients with HoFH that work independently of LDL receptors; and Outline patient-centered strategies to maximize quality of life for patients with HoFH on lipid-lowering therapies.
Please visit answersincme.com/YSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss timely diagnosis of diabetic macular edema (DME) and treatment with anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Recognize best practices to achieve a prompt and accurate diagnosis of DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DME; and Review the clinical profiles of longer-acting VEGF-targeted agents with phase 3 trial evidence in the treatment of DME.
Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.
Please visit answersincme.com/EKH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses frontline immunotherapy-based combination strategies to improve outcomes in patients with advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Review the rationale for including immunotherapy as a component of a therapeutic approach for patients with advanced biliary tract cancer (BTC); Describe the clinical profiles of immunotherapy plus chemotherapy combinatorial approaches for the treatment of advanced BTC; and Outline practical strategies to enhance evidence-based care of patients with advanced BTC on a combined immunotherapy plus chemotherapy approach.
Please visit answersincme.com/XTX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in cardiology discuss the diagnosis and management of homozygous familial hypercholesterolemia (HoFH). Upon completion of this activity, participants should be better able to: Describe the clinical impact of early and intensive treatment for patients with HoFH; Identify patients with HoFH through differential diagnosis; and Review the clinical profiles of novel strategies to reduce low-density lipoprotein (LDL).
Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.
Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.
Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.
Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.
Please visit answersincme.com/PBR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in managing hypertrophic cardiomyopathy (HCM) discuss best practices for diagnosis and evidence-based strategies using cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Identify best practices to optimally diagnose patients with HCM in order to improve patient outcomes; Describe the clinical impact of cardiac myosin inhibitors in managing patients with obstructive HCM; and Outline practical strategies to incorporate cardiac myosin inhibitors into treatment plans for patients with obstructive HCM.
Please visit answersincme.com/YYB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for selecting anti-VEGF therapy and maintaining adherence for patients with diabetic macular edema. Upon completion of this activity, participants should be better able to: Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with diabetic macular edema (DME); Review the clinical profiles of longer-acting vascular endothelial growth factor (VEGF)-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy.
Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adjuvant chemotherapy for patients with early-stage non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for adjuvant immunotherapy in patients with early-stage non–small-cell lung cancer (NSCLC) following surgery and chemotherapy; Review the clinical profiles of approved and emerging adjuvant immunotherapy regimens in early-stage NSCLC; and Outline factors that optimize integration of adjuvant immunotherapy regimens for early-stage NSCLC into clinical practice.
Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients with moderate-to-severe atopic dermatitis (AD); Describe the clinical profiles of targeted systemic therapies that are approved for pediatric patients with moderate-to-severe AD; and Outline patient-centered strategies to enhance long-term outcomes for pediatric patients with moderate-to-severe AD who are candidates for targeted systemic therapies.
Please visit answersincme.com/CKS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses when to use SGLT2 inhibitors in patients with chronic kidney disease. Upon completion of this activity, participants should be better able to: Describe the benefits of SGLT2 inhibitor use in the management of CKD; Define strategies for the early implementation of SGLT2 inhibitor therapy in CKD; and Identify appropriate patient populations for the early implementation of SGLT2 inhibitor therapy in CKD.
Please visit answersincme.com/MUP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the importance of early detection and referral of patients with retinal vein occlusion (RVO), as well as a personalized and multidisciplinary approach to management. Upon completion of this activity, participants should be better able to: Recognize the rationale for early detection of RVO; Describe the appropriate processes for timely referral of patients with RVO; and Outline strategies for personalized, multidisciplinary management of patients with RVO.
Please visit answersincme.com/UPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in allergy and respiratory disease discuss patient-centered strategies to improve treatment of children with asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.
Please visit answersincme.com/TZQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in clinical oncology discusses optimizing patient outcomes with immunotherapy-based combination approaches in unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Recognize the role of available and recently approved immunotherapy-based combination regimens for the management of unresectable HCC; Outline the practical implications of the clinical trial data evaluating available and recently approved immunotherapy-based combination regimens for unresectable HCC; and Review a personalized approach to optimize patient outcomes on available and recently approved immunotherapy-based combination regimens, thus enhancing quality of life.
Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.
Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss guideline-recommended systemic treatment options and strategies to optimize long-term care for patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of VHL disease-associated RCC; Describe the clinical impact of current guideline-recommended systemic treatment options for VHL disease-associated RCC; and Identify strategies to optimize long-term care for patients with VHL disease-associated RCC.
Please visit answersincme.com/MMD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in multiple myeloma discuss triplet combination therapies and treatment selection in relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Explain current guideline recommendations to optimize clinical treatment plans for patients with RRMM; Review the clinical implications of the latest data for triplet regimens containing an anti-CD38 monoclonal antibody, proteasome inhibitors, and chemotherapy in special patient populations with RRMM; and Identify additional monitoring strategies for special patient subgroups with RRMM based on the latest clinical evidence and expert guidance.
Please visit answersincme.com/FXY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses atypical antipsychotics in the treatment of bipolar I disorder. Upon completion of this activity, participants should be better able to: Identify strategies to improve the diagnostic accuracy of bipolar I disorder (BD-I); Review the clinical profiles of atypical antipsychotics for the treatment of BD-I; and Outline opportunities to individualize treatment for patients with BD-I, based on patient-, disease-, and drug-specific characteristics.
Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand and foot dermatitis; and Outline future treatment considerations to optimize the use of novel systemic therapies in patients with moderate-to-severe atopic hand and foot dermatitis.
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
Please visit answersincme.com/YXX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics discusses respiratory syncytial virus (RSV) vaccines for infants. Upon completion of this activity, participants should be better able to: Recognize the rationale for considering respiratory syncytial virus (RSV) vaccines for infants; Describe the clinical profiles of emerging long-acting monoclonal antibodies and maternal vaccines for preventing RSV in infants; and Outline strategies for optimal integration of emerging agents, including overcoming barriers to vaccination, for improving patient outcomes.
Please visit answersincme.com/MPP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts—a medical oncologist and an oncology nurse practitioner—discuss a multidisciplinary approach to holistic management of hand-foot skin reaction (HFSR) from multikinase inhibitor therapy in patients with colorectal cancer (CRC). Upon completion of this activity, participants should be better able to: Recognize the impact of hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for holistic management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education and practical shared communication strategies to help manage HFSR.
Please visit answersincme.com/HQX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of eosinophilic esophagitis (EoE) discuss biologic therapies targeting type 2 inflammation. Upon completion of this activity, participants should be better able to: Identify the role of type 2 inflammation in EoE in the context of treatment implications; and Describe evidence-based strategies to integrate biologics targeting type 2 inflammation into clinical practice for the management of EoE.
Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.
Please visit answersincme.com/EUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology and oncology discuss the role of cereblon E3 ligase modulators in patients with relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating cereblon (CRBN) E3 ligase modulators (CELMoDs) as therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM); Describe the clinical profiles of emerging CELMoDs for patients with RRMM; and Outline evidence-based strategies to optimize sequencing to CELMoDs for patients with RRMM, as they become available.
Please visit answersincme.com/EXY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses the disease severity assessment and treatment of patients with moderately to severely active ulcerative colitis (UC).Upon completion of this activity, participants should be better able to: Identify appropriate strategies to effectively assess disease severity in ulcerative colitis; Describe the rationale for Janus kinase (JAK) inhibitors in targeting the disease pathophysiology in patients with ulcerative colitis; and Outline strategies to individualize the treatment selection for patients with ulcerative colitis.
Please visit answersincme.com/BAV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses Bruton’s tyrosine kinase (BTK) inhibitors in relapsing multiple sclerosis (MS). Upon completion of this activity, participants should be better able to: Recognize the biologic rationale for therapeutically targeting BTK in MS; Describe the clinical impact of late-stage emerging BTK inhibitors in relapsing MS; and Outline clinical considerations for the future use of BTK inhibitors in the management of relapsing MS.
Please visit answersincme.com/BCJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses JAK inhibitor therapy for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Identify early signs of ruxolitinib failure for timely risk stratification of patients with myelofibrosis (MF); Describe the clinical profiles of novel JAK inhibitors for the treatment of patients with MF; and Outline evidence-based strategies to optimize JAK inhibitor therapy for patients with MF.
Please visit answersincme.com/QTQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma discusses treatment sequencing in relapsed/refractory multiple myeloma (RRMM) and the integration of novel CAR T-cell therapies into the treatment paradigm. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma; Review the significance of the latest clinical data for the use of CAR T cells in pretreated patients with RRMM; and Outline clinical factors that may inform treatment sequencing strategies to optimize outcomes for patients.
Please visit answersincme.com/CTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infections and vaccination discusses the rationale for respiratory syncytial virus (RSV) vaccination in older adults and how late-stage emerging vaccines can lower their risk of RSV infection. Upon completion of this activity, participants should be better able to: Recognize the burden of disease associated with RSV in older adults; Describe the clinical rationale for vaccines to prevent RSV in older adults; and Evaluate the latest clinical data for late-stage investigational RSV vaccines in older adults.
Please visit answersincme.com/REP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology and a patient advocate share their perspectives on the impact of social determinants of health on outcomes for patients with nonvalvular atrial fibrillation (NVAF) and strategies to optimize care for patients experiencing disparities. Upon completion of this activity, participants should be better able to: Recognize the impact of social determinants of health (SDOH) on cardiovascular disease outcomes, focusing on nonvalvular atrial fibrillation (NVAF); Describe patient-centered approaches to enhance the detection and assessment of adverse SDOH in patients with NVAF; and Outline community-based strategies to optimize care for patients with NVAF experiencing disparities.
Please visit answersincme.com/VKP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses patient profiles, disease factors, and other ways to optimize treatment of patients with advanced gastroesophageal junction and esophageal cancers. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of first-line immunotherapy-based combination regimens for the management of patients with advanced gastroesophageal junction (GEJ) and esophageal cancers; Identify clinical and disease factors that can be used to personalize first-line treatment selection for patients with advanced GEJ and esophageal cancers; Review clinical strategies to optimize quality of care for patients with advanced GEJ and esophageal cancers on immunotherapy-based combination regimens.
Please visit answersincme.com/DMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease discuss the clinical impact of mRNA-based COVID-19 vaccines. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available mRNA-based COVID-19 vaccines; Evaluate the clinical impact of available mRNA-based COVID-19 vaccines; and Apply region-specific, patient-centered strategies to optimize uptake of mRNA-based COVID-19 vaccination.
Please visit answersincme.com/ADT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses combination locoregional and systemic therapies in advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for combining locoregional therapies with immunotherapies to treat advanced NSCLC; Describe the clinical implications for combining novel locoregional therapies with systemic immunotherapy for advanced NSCLC; and Outline practical strategies to optimize treatment for combination therapy in advanced NSCLC.
Please visit answersincme.com/PGS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses integrating non-steroidal mineralocorticoid receptor antagonists (MRAs) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.
Please visit answersincme.com/DCF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in chronic kidney disease discuss the importance of early detection and optimized management by both primary care physicians and nephrologists. Upon completion of this activity, participants should be better able to: Identify the role of timely assessment and early diagnosis in optimizing outcomes in patients with chronic kidney disease (CKD); Describe approved and emerging pharmacologic treatment options for patients with CKD; and Outline patient-centered strategies to maximize patient care in CKD.
Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.
Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for patients with PN; Describe the clinical profiles of approved and emerging biologic therapies for the treatment of PN; and Outline approaches to optimally integrate biologic therapies into treatment plans for PN.
Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.
Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.
Please visit answersincme.com/EUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses new treatments for patients with presbyopia. Upon completion of this activity, participants should be better able to:Recognize the unmet therapeutic needs with available presbyopia treatments; Describe the evidence for late-stage emerging miotic agents being developed to treat presbyopia; and Outline strategies to individualize treatment selection for patients with presbyopia.
Please visit answersincme.com/ZWK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology and oncology discusses B-cell maturation antigen (BCMA)–targeted strategies for the treatment of multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the latest evidence for investigational regimens containing BCMA-targeted immunotherapies for earlier lines of multiple myeloma (MM) treatment; Evaluate the clinical impact of combining late-stage emerging, BCMA-targeted strategies with standard of care (SOC) for earlier lines of MM treatment; and Identify strategies to optimally incorporate novel BCMA-containing therapies into the current treatment paradigm, as they become available, for patients with MM.
Please visit answersincme.com/WBE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses how new and emerging therapeutic options targeting type 2 inflammation can improve quality of life for patients with eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for targeting type 2 inflammatory factors to treat EoE; and Outline individual approaches to optimize therapeutic regimens for patients with EoE.
Please visit answersincme.com/CUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses treatment options for non-radiographic axial spondyloarthritis (nr-axSpA). Upon completion of this activity, participants should be better able to: Recognize guideline-recommended treatment options used to reduce the burden of non-radiographic axial spondyloarthritis (nr-axSpA) on patients; Describe the clinical impact of approved and late-stage emerging agents for the treatment of nr-axSpA; and Outline clinical considerations for the role of approved and late-stage emerging agents in the treatment landscape of nr-axSpA.
Please visit answersincme.com/DRN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses emerging small molecule therapies in the treatment of moderate-to-severe Crohn’s disease. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using emerging selective Janus kinase (JAK) inhibitors and sphingosine 1–phosphate (S1P) receptor modulators in Crohn’s disease; Describe evidence from late-stage clinical trials on the use of small molecule therapies in individuals with moderate-to-severe Crohn’s disease; and Outline patient-centered strategies for optimizing treatment with small molecule therapies in moderate-to-severe Crohn’s disease.
Please visit answersincme.com/FKQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Anne O’Donnell, an expert in pulmonology, discusses the role of diagnostic imaging in the diagnosis of non–cystic fibrosis bronchiectasis (NCFB). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of early diagnosis of non–cystic fibrosis bronchiectasis (NCFB); Identify NCFB based on diagnostic imaging; and Describe the clinical profiles of novel and emerging neutrophil-targeted therapies for NCFB.
Please visit answersincme.com/TVT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in endocrinology discusses how to optimize the use of novel non-steroidal mineralocorticoid receptor antagonists (MRAs) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.
Please visit answersincme.com/GDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the clinical impact of approved and emerging combination treatments for advanced melanoma. Upon completion of this activity, participants should be better able to: Identify the unmet treatment needs for patients with advanced melanoma within the current therapeutic landscape; Recognize the mechanism of action of anti-lymphocyte activation gene-3 (anti-LAG-3) plus programmed cell death protein 1 (PD-1) combinations for the treatment of advanced melanoma; and Describe the clinical impact of approved and emerging anti-LAG-3 plus PD-1 combinations for the treatment of advanced melanoma.
Please visit answersincme.com/GVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neuro-oncology discusses novel adjuvant therapies for patients with newly diagnosed glioblastoma. Upon completion of this activity, participants should be better able to: Recognize the rationale for combining tumor-treating fields (TTFields) with immunotherapy in the adjuvant treatment of newly diagnosed glioblastoma; Compare the clinical impact of emerging TTFields plus immunotherapy regimens and standard of care in the adjuvant treatment of newly diagnosed glioblastoma; and Outline strategies to personalize the selection of adjuvant therapy for patients with newly diagnosed glioblastoma.
Please visit answersincme.com/PRH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses the guideline-recommended approach to incorporating non-steroidal mineralocorticoid receptor antagonists (MRAs) into the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Describe the role of non-steroidal MRAs in the treatment of patients with CKD and T2D; Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Review the latest guideline updates informing the use of novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.
Please visit answersincme.com/AXS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Adam S. Wenick, an expert in ophthalmology, discusses treatment adherence in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal vascular endothelial growth factor– (VEGF-) targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Review patient counseling approaches to improve treatment adherence to intravitreal VEGF-targeted therapies for nAMD.
Please visit answersincme.com/RUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for using intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.
Please visit answersincme.com/BWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses how to identify children with uncontrolled asthma who could benefit from an add-on biologic. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with add-on biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.
Please visit answersincme.com/WPZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the use of noninvasive tools in the diagnosis and management of nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the role of noninvasive tools in effectively diagnosing and monitoring patients with NASH; Identify strategies to translate real-world evidence on noninvasive tools into clinical practice; and Recognize the impact of timely diagnosis on improving hepatic outcomes in patients with NASH.
Please visit answersincme.com/YWV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses treatment of children with uncontrolled asthma using biologic therapies. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment intensification with a biologic; Review the clinical profiles of current biologics used in the management of moderate-to-severe asthma in children; and Outline evidence-based strategies to optimize outcomes for pediatric patients with moderate-to-severe asthma who require biologics.
Please visit answersincme.com/DUR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an allergist and immunologist discusses individualized treatment for children with moderate-to-severe asthma. Upon completion of this activity, participants should be better able to: Identify pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from add-on biologic therapy; Describe the clinical profiles of available biologics for the management of inadequately controlled moderate-to-severe asthma in pediatric patients; and Outline strategies to provide individualized, evidence-based treatment for inadequately controlled moderate-to-severe asthma in pediatric patients.
Please visit answersincme.com/GZT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the latest data in systemic treatments for children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the rationale for treatment intensification with novel systemic agents when managing children with moderate-to-severe atopic dermatitis (AD); Review the latest clinical data informing the current and future use of novel systemic agents in children with moderate-to-severe AD; and Identify opportunities for shared decision-making to improve the care of children with moderate-to-severe AD.
Please visit answersincme.com/QND860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses integrating anti–vascular endothelial growth factor (anti-VEGF) agents into treatment strategies for diabetic retinopathy (DR) and diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.
Please visit answersincme.com/DNQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urology discusses the gap in prostate cancer outcomes for Black men. Upon completion of this activity, participants should be better able to: Recognize clinical challenges in the management of prostate cancer in Black men; Describe the clinical impact of GnRH antagonists used for androgen deprivation therapy, in comparison to GnRH agonists, in men with advanced prostate cancer; and Outline patient-centered approaches to optimize outcomes for Black men with advanced prostate cancer who are eligible for androgen deprivation therapy.
Please visit answersincme.com/YBC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the evidence for combining immune checkpoint inhibitors (ICIs) with chemotherapy in the treatment of advanced biliary tract cancer and provides a clinical perspective on the future role of these combinations in the treatment landscape. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating ICI plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Discuss the efficacy and safety of late-stage emerging ICI plus chemotherapy combinations being investigated for the first-line treatment of advanced biliary tract cancer, compared to conventional therapy options; and Summarize clinical considerations for the future use of emerging ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.
Please visit answersincme.com/XWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology, discusses immunotherapy-based combination regimens for the first-line treatment of unresectable HCC. Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for immunotherapy-based combination treatment regimens for the management of unresectable hepatocellular carcinoma (HCC) in the first-line setting; Review the clinical implications of the latest efficacy and safety data for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; and Describe patient selection strategies for available first-line combination immunotherapy-based regimens in unresectable HCC.
Please visit answersincme.com/YCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses anti-VEGF treatment of diabetic retinopathy with or without diabetic macular edema. Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.
Please visit answersincme.com/HNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in weight loss, discusses strategies to optimize therapy for weight loss in patients with type 2 diabetes and obesity. Upon completion of this activity, participants should be better able to: Review key clinical data for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA in patients with T2D and obesity, and Outline shared decision-making strategies to optimize therapy in patients with T2D and obesity.
Please visit answersincme.com/ACJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses BRCA testing in patients with early-stage breast cancer. This activity also features a patient who shares her experience about genomic testing when being treated for early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the growing importance of comprehensive genomic testing, including BRCA1/2 mutational testing, in patients with early-stage breast cancer; Outline practical, patient-centered strategies to facilitate BRCA1/2 mutational testing in patients with early-stage breast cancer; and Evaluate the clinical significance of the latest trial data for neoadjuvant and adjuvant treatment of patients with BRCA-mutated, early-stage breast cancer.
Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education to promote self-management.
Please visit answersincme.com/NMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses rationale for—and clinical impact of—cereblon (CRBN) E3 ligase modulators (CELMoDs) in treating relapsed/refractory multiple myeloma (RRMM), including clinical considerations for their future use. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating novel therapies to address unmet treatment needs for relapsed/refractory multiple myeloma; Review the biologic rationale for targeting cereblon with novel therapies for RRMM; Describe the clinical impact of emerging CRBN E3 ligase modulators in patients with RRMM; and Outline clinical considerations for the integration of CRBN E3 ligase modulators in the future management of RRMM.
Please visit answersincme.com/MTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in eosinophilic gastrointestinal disease discusses the diagnosis and underlying pathophysiology targeted by potential treatments for eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Describe the burden associated with delayed detection and inadequate treatment of EoE; Identify strategies to provide timely diagnosis of EoE; and Recognize the therapeutic rationale for targeting type 2 inflammation factors to treat EoE.
Please visit answersincme.com/EUT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses glioblastoma multiforme (GBM). Upon completion of this activity, participants should be better able to: Identify opportunities to personalize adjuvant treatment for patients with newly diagnosed glioblastoma multiforme (GBM); Describe practical approaches to manage adverse events associated with adjuvant therapies in patients with newly diagnosed GBM; and Outline strategies to monitor patients with newly diagnosed GBM on adjuvant therapies to improve patient outcomes.
Please visit answersincme.com/VSA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses how racial disparities may impact the management of Black patients with anemia of chronic kidney disease (CKD) and how to address these disparities. Upon completion of this activity, participants should be better able to: Identify the racial disparities that affect Black patients with anemia of CKD, leading to suboptimal outcomes; Recognize underlying factors contributing to racial disparities in the management of Black patients with anemia of CKD; and Outline strategies to improve the individualized treatment and management of anemia of CKD among Black patients.
Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert on immunization discusses the mechanisms of COVID-19 vaccines, the clinical impact of viral vector–based vaccines and how to improve communication with patients regarding vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available COVID-19 vaccines; Evaluate the clinical impact of available viral vector–based COVID-19 vaccines; and Apply patient-centered counseling strategies to enhance communication with patients to improve COVID-19 vaccine acceptance.
Please visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.
Please visit answersincme.com/TAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in infectious diseases discusses the early identification and treatment of patients with COVID-19 who are at a higher risk of progression to severe illness. Upon completion of this activity, participants should be better able to: Identify nonhospitalized patients with COVID-19 who have risk factors for progression to severe illness; Describe national guideline recommendations for the therapeutic management of nonhospitalized patients with COVID-19 who are at risk for progression to severe illness; and Outline a personalized management approach to enhance outcomes for nonhospitalized patients who are diagnosed with COVID-19 and are at risk for progression to severe illness.
Please visit answersincme.com/MYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses best practices in diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize best practices to optimize the prompt and accurate diagnosis of diabetic retinopathy (DR) and diabetic macular edema (DME); and Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME.
Please visit answersincme.com/AFP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the most up-to-date recommendations and clinical evidence on oral calcitonin gene-related peptide (CGRP)–targeted therapies for the acute and preventive management of migraine disease. Upon completion of this activity, participants should be better able to: Review the latest American Headache Society consensus statement recommendations for the treatment of migraine disease; Describe the latest clinical evidence on approved oral CGRP-targeted therapies in the management of migraine disease; and Outline practical, patient-centered strategies to optimize the use of oral CGRP-targeted therapies in the management of migraine disease.
Please visit answersincme.com/YXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing for multiple tumors, as well as the available testing methodologies and best practices to personalize care. Upon completion of this activity, participants should be better able to: Recognize the importance of biomarker testing in improving patient outcomes in multiple cancers; Review biomarker testing methodologies available to evaluate for the presence of actionable mutations and biomarkers; and Outline provider-level, multidisciplinary best practices to optimize biomarker testing in clinical practice.
Please visit answersincme.com/JZM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal vein occlusion (RVO) discusses selecting among and incorporating anti-vascular endothelial growth factor (VEGF) therapy into treatment plans for patients with macular edema (ME) secondary to RVO. Upon completion of this activity, participants should be better able to: Evaluate the benefit-risk profiles of available anti-VEGF treatments for patients with macular edema secondary to RVO; Discuss practical approaches to optimally incorporate anti-VEGF agents into treatment plans for patients with RVO; and Apply strategies to counsel patients on the use of anti-VEGF agents for RVO to optimize patient outcomes.
Please visit answersincme.com/YUM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for better referral and treatment for patients with diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for timely patient referral to ophthalmologic specialists for an evaluation of diabetic retinopathy (DR) and diabetic macular edema (DME) in appropriate patients; Outline strategies for use in primary care to enhance outcomes for patients who are at risk of, or who have developed, DR and DME; and Review the clinical impact of available vascular endothelial growth factor (VEGF)-targeted agents for use in DR and DME.
Please visit answersincme.com/JTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in major depressive disorder discusses ways to individualize use of second-line treatment approaches. Upon completion of this activity, participants should be better able to: Identify symptoms and patient characteristics that may inform the use of second-line therapies for patients with major depressive disorder (MDD); Choose second-line treatment approaches for patients with MDD based on individualized factors; and Discuss practical strategies to improve patient communication and set treatment expectations.
Please visit answersincme.com/CHA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer management discusses current and future treatment strategies to manage patients with advanced nonmelanoma skin cancer (NMSC), including cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Propose patient and disease-related factors that could help determine the optimal treatment strategies for patients suffering from advanced NMSC; Describe the efficacy and safety of immunotherapies in the management of the most common NMSCs, BCC and CSCC; Identify the potential place of immunotherapies in the treatment plan for patients with NMSC.
Please visit answersincme.com/FGW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the latest evidence on the efficacy and safety of anti–amyloid-β immunotherapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for selectively targeting neurotoxic soluble amyloid-β oligomers in early-stage AD; Discuss the clinical implications of the efficacy and safety profiles for emerging late-stage selective anti–amyloid-β immunotherapies; and Propose evidence-based, patient-centered strategies to integrate emerging selective anti–amyloid-β into a therapeutic plan to improve clinical outcomes.
Please visit answersincme.com/DZK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in infectious diseases discusses the latest evidence on managing nontuberculous Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing how available and emerging treatment regimens may address gaps in care for nontuberculous MAC lung disease; and Apply clinical strategies to optimize the management of patients with nontuberculous MAC lung disease.
Please visit answersincme.com/USX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses biologic therapy for moderate-to-severe asthma. Upon completion of this activity, participants should be better able to:; Outline the latest clinical data informing the use of biologic therapies to optimize the long-term management of moderate-to-severe asthma; and Translate the latest clinical data to practice to individualize treatment intensification for patients with persistent asthma who are inadequately managed.
Please visit answersincme.com/KAN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiotherapy and medical oncology for thoracic and genitourinary cancers discusses first-line use of new therapeutic options for malignant pleural mesothelioma, including tumor treating fields and immunotherapy. Upon completion of this activity, participants should be better able to: Assess the latest safety and efficacy data for current first-line options used for the treatment of malignant pleural mesothelioma (MPM); Identify patient-, disease-, and drug-related factors that may inform the first-line use of new therapeutic options for MPM; and Use patient-centered care strategies to guide treatment selection and address quality of life concerns.
Please visit answersincme.com/SBK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses the role of novel electric field therapies in treating solid tumors. Upon completion of this activity, participants should be better able to: Describe the rationale for incorporating novel electric field therapies into the management of patients with solid tumors; Outline approaches to counsel patients on the use of novel electric field devices as part of the treatment plan for cancer management; and Apply practical strategies to balance the efficacy and safety of novel electric field therapies to maximize patient outcomes.
Please visit answersincme.com/BMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in respiratory infections discusses the identification and treatment of patients with Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Outline strategies to optimize the timely diagnosis of Mycobacterium avium complex (MAC) lung disease; Identify patients with MAC lung disease who may benefit from the use of guideline-recommended antibiotic therapies to treat their disease; and Describe emerging late-stage antibiotic therapies being investigated to address first-line treatment gaps for patients with MAC lung disease.
Please visit answersincme.com/DKF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in upper respiratory infections discusses treatment of chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Outline evidence-based strategies to individualize treatment selection and ongoing management for patients with CRSwNP; and Identify patient-centered approaches to optimize outcomes and encourage long-term adherence to CRSwNP treatment.
Please visit answersincme.com/VFW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the evolving role of antibody drug conjugates (ADCs) in managing solid tumors. Upon completion of this activity, participants should be better able to: Describe the mechanism of action of antibody-drug conjugates for cancer treatment; Recognize the potential clinical profile of available antibody-drug conjugates to treat various solid tumor types; and Review how to integrate available antibody-drug conjugates for solid tumors into a therapeutic treatment plan for patients with relevant solid tumors.
Please visit answersincme.com/QNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses shingles prevention strategies for patients with immune-mediated diseases. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical burden of shingles; Evaluate the current recommendations and clinical evidence on shingles vaccination in patients with immune-mediated diseases; and Implement patient-centered, evidence-based strategies to improve shingles vaccine uptake and series completion.
Please visit answersincme.com/JEB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses evolving first-line therapeutic strategies to optimize the management of patients with unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Review the clinical evidence informing guideline recommendations for the first-line systemic treatment of patients with advanced HCC; Outline individualized first-line treatment plans for patients with advanced HCC, based on patient- and disease-related factors; and Describe long-term management strategies to optimize outcomes and survivorship for patients with advanced HCC receiving systemic first-line therapies.
Please visit answersincme.com/XJF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging options for adjuvant treatment of early non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options in surgically resected, early-stage NSCLC; Describe the clinical profile of current and emerging adjuvant immunotherapy options for the management of surgically resected, early-stage NSCLC; and Identify potential candidates with surgically resected, early-stage NSCLC for adjuvant treatment with immunotherapy based on patient-specific characteristics.
Please visit answersincme.com/TNC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of current and emerging selective estrogen receptor degraders (SERDs) in managing patients with estrogen receptor positive breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical profile of selective estrogen receptor degraders (SERDs) in the management of patients with estrogen receptor positive breast cancer; Outline the role of current and emerging SERDs in the management of estrogen receptor positive breast cancer, based on available clinical evidence; and Discuss clinical factors that are relevant when assessing current and emerging SERD options, based on available clinical evidence.
Please visit answersincme.com/PAP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in genitourinary oncology discusses targeted treatments for advanced urothelial carcinoma. Upon completion of this activity, participants should be better able to: Review the approved and emerging targeted treatment options for patients with advanced urothelial carcinoma (UC) progressing on first- or second-line of therapy; Describe the available clinical data on targeted treatment options for patients with advanced UC who have progressed on immunotherapy; and Outline evidence-based strategies to optimize outcomes for patients with advanced UC who have progressed on immunotherapy.
Please visit answersincme.com/ZBK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the latest evidence in treatment of children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the impact that moderate-to-severe atopic dermatitis (AD) has on children, and the rationale for systemic treatment to improve patient quality of life; Identify the most recent clinical data for the use of systemic therapies in children with moderate-to-severe AD; and Translate the latest evidence regarding systemic therapies into management strategies for children with moderate-to-severe AD, now and in the future.
Please visit answersincme.com/VSF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in atopic dermatitis (AD) discusses balancing treatment efficacy and safety along with patient perspectives to optimize the management of moderate-to-severe AD. Upon completion of this activity, participants should be better able to: Differentiate the efficacy and safety of biologic and small molecule systemic therapies used in the treatment of moderate-to-severe AD based on recent clinical evidence; Identify patient-, disease-, and drug-related factors that may be used to individualize the use of systemic treatments for moderate-to-severe AD; and Design individualized treatment plans incorporating the patient perspective to balance the efficacy and safety of moderate-to-severe AD treatment.
Please visit answersincme.com/RKA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric dermatology discusses identifying and treating moderate-to-severe atopic dermatitis (AD) using two patient cases. Upon completion of this activity, participants should be better able to: Identify patients who have moderate-to-severe AD and may benefit from intensified therapy; Outline the latest evidence for biologic therapies that may be used for the treatment of patients with moderate-to-severe AD now and into the future; and Apply practical approaches to optimize the management of patients with moderate-to-severe AD long-term.